![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, September 17, 2006 7:54:42 PM
In addition to all the abstracts posted over on the YH board recently (and compiled on Erbse's German Cortex board), here's a few more I found. Boehringer Ingelheim has this abstract on their compound BIIR-777. Boehringer has patents mainly in the Benzothiadiazine and related areas, so this compound is probably from that general family, although BI also had some benzoxazine patents as I recall (CX-614 is a benzoxazine). It looks like BIIR-777 has an 8.5 hour halflife -
Program#/Poster#: 267.2/GG19
Title: Effects of the positive allosteric AMPA receptor modulator BIIR 777: In vitro and in vivo studies
Location: Georgia World Congress Center: Halls B3-B5
Presentation Start/End Time: Sunday, Oct 15, 2006, 2:00 PM - 3:00 PM
Authors: *T. WEISER1, K. WINTER2, K. KLINDER3, T. OSUGI4, A. CECI1;
1CNS Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GERMANY, 2Quality Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, 3Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GERMANY, 4R&D Project Management, Boehringer Ingelheim US, Rigdefield, CT.
Positive modulation of AMPA-receptor mediated neurotransmission is a promising approach for the treatment of disorders affecting learning and memory. Here we describe the effects of BIIR 777, a novel and selective AMPA receptor modulator. In patch-clamp experiments using rat cortical neurons, or cells transfected with human GluR1/2, BIIR 777 significantly reduced desensitisation at concentrations >1 µM without affecting agonist potency. Investigating selectivity in >65 binding assays showed that the compound was highly selective. In anaesthetised rats, the excitatory local effect of AMPA on electrical activity of CA1 pyramidal hippocampal neurons was significantly increased in response to iontophoretic coadministration with BIIR 777. The systemic administration of BIIR 777 increased firing frequencies of pyramidal neurons in the CA1 region of the hippocampus, as well as in prefrontal cortex (CG3; at doses of 0.1 to 0.3 mg/kg i.v.). Pharmakokinetic investigations showed that BIIR 777 was orally available, penetrated the blood-brain barrier well, and had a plasma halflife of 8.5 h after oral administration. Thus, this compound was suitable for further in vivo models of learning and memory. In the passive avoidance test in rats, 30 mg/kg p.o. significantly reduced the proamnesic effect of alprazolam (0.45 mg/kg i.p.). In the rat object recognition test, BIIR 777 significantly augmented memory at 3, 10, and 30 mg/kg p.o.
These data show that BIIR 777 is a potent positive allosteric modulator of AMPA receptor function with promising properties in models of learning and memory in vivo.
Disclosures: T. Weiser, Boehringer Ingelheim, A. Employment (full or part-time) ; K. Winter, Boehringer Ingelheim, A. Employment (full or part-time) ; K. Klinder, Boehringer Ingelheim, A. Employment (full or part-time) ; T. Osugi, Boehringer Ingelheim, A. Employment (full or part-time) ; A. Ceci, Boehringer Ingelheim, A. Employment (full or part-time) .
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM